Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incorporating CT-Derived Body Composition Analysis Into the Global Leadership Initiative on Malnutrition Criteria Is Associated With Overall Survival: Findings From an International Cancer Cohort.

Journal of the Academy of Nutrition and Dietetics·2026

Same author

Letter to the Editor: Olanzapine as an Appetite Stimulant in Advanced Cancer - Do the Risks Outweigh the Benefits? A Note of Caution for Clinicians.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Perceptions and use of behaviour change interventions for physical activity in chronic respiratory disease in The Republic of Ireland.

Physiotherapy·2025

Same author

Using Audit to Improve End-of-Life Care in a Tertiary Cancer Centre.

Current oncology (Toronto, Ont.)·2025

Same author

The Global Leadership Initiative on Malnutrition (GLIM) inflammation criteria to predict survival in patients with advanced cancer: A prospective cohort study.

Clinical nutrition ESPEN·2025

Same author

Anaplastic Lymphoma Kinase (ALK)-Rearranged Renal Cell Carcinoma: A Case Report Highlighting Diagnostic Challenges and Therapeutic Opportunities.

Cureus·2024

Search research articles

Related Experiment Video

Updated: May 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Sorafenib-induced tuberculosis reactivation.

MinYuen Teo¹, Terence M O'Connor, Seamus P O'Reilly

¹Department of Medical Oncology, Mercy University Hospital, Cork, Ireland. neuy924@gmail.com

|September 26, 2012

Summary

This summary is machine-generated.

Sorafenib, used for cancer treatment, may trigger latent tuberculosis reactivation. Vigilance and screening for tuberculosis are recommended for patients on sorafenib therapy.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Last Updated: May 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

Oncology
Infectious Diseases
Immunology

Background:

Sorafenib is a multikinase inhibitor approved for renal cell carcinoma and hepatocellular carcinoma.
In vitro studies suggest sorafenib can inhibit immune cells and cytokines crucial for maintaining latent tuberculosis (TB) granulomas.

Observation:

A 74-year-old male with metastatic renal cell carcinoma experienced productive cough, sweats, and weight loss while on sorafenib.
Thoracic CT revealed lung consolidation and cavitation; sputum analysis confirmed active tuberculosis.
The patient was diagnosed with sorafenib-induced tuberculosis reactivation.

Findings:

Sorafenib treatment was discontinued, and anti-tuberculous antibiotics were initiated.
The patient showed symptomatic and radiographic improvement after treatment modification.

Implications:

Sorafenib may increase the risk of latent tuberculosis progressing to active disease.
Healthcare providers should consider screening patients for latent TB before initiating sorafenib.
Increased vigilance for tuberculosis symptoms is warranted in patients receiving sorafenib.